Translational Drug Development (TD2)
Susan Tessmann's work experience begins in 1991 at Covance, where they held various positions including Senior HR Generalist/HR Generalist, Senior Manager in Toxicology, and Senior Project Manager. Susan'sresponsibilities at Covance included managing projects, overseeing clinical trials, developing client relationships, and providing HR support and guidance.
In 2006, they transitioned into the role of Director, HR Business Partner, Clinical Development Services at Covance. In this role, they were responsible for culture development, talent development, and succession planning initiatives. Susan also provided guidance on training activities and ensured appropriate compensation packages for employees.
In 2016, Susan joined Translational Drug Development (TD2) as Director of Clinical Operations. Susan'srole involved overseeing the TD2 oncology clinical team, managing operational aspects of oncology clinical trials, and participating in the development and reporting of clinical data.
Then in 2018, they were promoted to Vice President of Clinical Development at TD2, where they currently serve.
Susan Tessmann obtained an MBA in Human Resources from the University of Phoenix in 2007. Prior to that, they earned a BS in Business Management from Edgewood College between 1997 and 2001. In 2014, they attended UC San Diego, but no degree or field of study is specified. Additionally, Susan has several additional certifications including Understanding Cancer Metastasis from The Johns Hopkins University School of Medicine in 2017, Project Management: The Basics for Success from Coursera Course Certificates in 2015, Certified Project Manager (CMP) from Project Management Leadership Group, Inc.(PMLG) in 2011, Targeted Selection Trainer from DDI | Development Dimensions International in 2005, DDI Learning Systems Trainer from DDI | Development Dimensions International in 2004, Project Management Professional (PMP) from Project Management Institute (PMI) in 2004, Six Sigma Greenbelt from Covance in 2003, and Professional in Human Resources certification from HR Certification Institute - HRCI in 2004.
This person is not in any offices
Translational Drug Development (TD2)
Translational Drug Development (TD2) is an oncology-focused Contract Research Organization (CRO) that supports improved and accelerated development of medicines for life-threatening diseases. We help companies move their drugs through the critical stages of preclinical, regulatory and clinical trial processes. Our scientific depth, proactive problem solving, and strategic direction and advice increase the likelihood of positive outcomes that bring hope and a better quality of life to cancer patients and their families. TD2 was born from the Translational Genomics Research Institute (TGen) as a nonprofit in 2003. TGen’s deep scientific expertise and approach to interrogating the “omic” drivers of disease is at the heart of TD2’s heritage and has become the foundation upon which TD2 creates unique clinical strategies for its clients.